GLSI 13.70 Greenwich LifeSciences, Inc.
| Range: | 7.58-21.44 | Vol Avg: | 32339 | Last Div: | 0 | Changes: | -0.67 |
| Beta: | 3.29 | Cap: | 0.18B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Sep 25 2020 | Empoloyees: | 3 | ||
| CUSIP: | 396879108 | CIK: | 0001799788 | ISIN: | US3968791083 | Country: | US |
| CEO: | Mr. Snehal S. Patel | Website: | https://greenwichlifesciences.com | ||||
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow